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SUMMARY – Th e aim was to evaluate the effi  cacy of a single-pill combination of atorvastatin/
amlodipine in patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular 
risk. Th is prospective study included 243 patients with arterial hypertension, dyslipidemia and moder-
ate to high cardiovascular risk, mean age 63.3±9.8 years. All patients were prescribed a treatment with 
one of the following doses of a single-pill combination of atorvastatin/amlodipine: 10/5, 10/10, 20/5 
or 20/10 mg daily. Th e follow-up period was 3 months. Th e mean baseline values of the systolic and 
diastolic blood pressure were 155.7±16.2 and 92.0±9.2 mm Hg, respectively. At month 3, the respec-
tive mean systolic and diastolic blood pressure values were 136.9±26.9 and 80.6±5.1 mm Hg. Th e 
mean baseline values of total cholesterol and low-density lipoprotein cholesterol were 6.6±1.2 and 
4.4±1.1 mmol/L, respectively. At month 3, the respective mean values of total cholesterol and low-
density lipoprotein cholesterol were 5.1±0.9 and 2.9±1.0 mmol/L. Treatment was discontinued in 9 
(3.7%) patients due to adverse events. In conclusion, treatment with the single-pill combination of 
atorvastatin/amlodipine was eff ective and well tolerated by the patients with arterial hypertension, 
dyslipidemia and moderate to high cardiovascular risk.
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Introduction
Arterial hypertension (HTN) and dyslipidemias 
are the most signifi cant risk factors (RF) for cardiovas-
cular (CV) complications worldwide1-4. HTN aff ects 
~22% of the world population (30%-45% in Europe 
and North America) and dyslipidemias ~39% of the 
population aged ≥25 years (54% of the Europeans)1-5.
In a number of epidemiological studies, elevated 
blood pressure (BP) and cholesterol have been identi-
fi ed as strong RF for coronary heart disease, cerebro-
vascular disease, peripheral arterial disease, etc.6-7. Re-
gardless of the existing pharmacological and non-
pharmacological options, control of these RF is unsat-
isfactory. At least 50% of patients with HTN and/or 
hypercholesterolemia in many countries of Europe, 
North America and Asia maintain BP and/or low-
density lipoprotein cholesterol (LDL-C) and/or total 
cholesterol (TC) levels above the target ones1,2,7. Each 
year ~8 million hypertensives die and another ~60 mil-
lion develop severe debilitating complications as a 
consequence of uncontrolled HTN5. Another 2.6 mil-
lion patients with dyslipidemia die yearly and about 30 
million are seriously disabled due to untreated or not 
eff ectively treated hypercholesterolemia8.
Th e contemporary combination antihypertensive 
and lipid-lowering strategies are based mostly on the 
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level of CV risk of the individual patient on the one 
hand, and on the BP, LDL-C and TC values (baseline 
and target ones) on the other hand5,8,9. Where possible, 
single-pill combinations (SPC) are widely recom-
mended because of the certain advantages over free 
combinations, i.e. standardized dose of the ingredients, 
facilitated treatment regimen with less tablets and of-
ten more aff ordable price5,8,11. Th ese features improve 
patient adherence to the prescribed treatment, and 
thus to HTN and dyslipidemia control11-13.
Th e SPC of atorvastatin/amlodipine in various 
proportions is one the most reasonable options for 
combination treatment in patients with HTN and hy-
percholesterolemia. Its pharmacokinetic and pharma-
codynamic features, as well as the proven clinical ben-
efi ts of each of the active components gave us grounds 
for conducting a prospective clinical study among out-
patients14-16.
Patients and Methods
A prospective, open-label study, conducted from 
March to August, 2014, included 243 consecutive out-
patients with HTN and dyslipidemia (128 (52.7%) 
males) from 20 Bulgarian cities, towns and villages, 
mean age 63.3±9.8 (range, 40-91) years. Th e study 
conductance was in accordance with ethical standards 
of the institutional or regional responsible committee 
on human experimentation and with the Helsinki 
Declaration of 1975, as revised in 1983. A written in-
formed consent was obtained from all patients before 
their enrolment in the study and an approval of the 
study was obtained from the local ethics committee.
Inclusion criteria
Th e study inclusion criteria were as follows: 1) pa-
tients with essential HTN and dyslipidemia (accord-
ing to the current European guidelines for diagnosis 
and treatment of these diseases); 2) patients on outpa-
tient antihypertensive and lipid-lowering therapy, not 
achieving the target BP and/or LDL-C values accord-
ing to the current European guidelines5,8 at ≥1 month 
of treatment initiation; 3) patients requiring antihy-
pertensive and lipid-lowering therapy according to the 
current European guidelines, but not receiving medi-
cation therapy before inclusion in the study; 4) feasible 
follow-up in the course of 3 months after initiation of 
atorvastatin/amlodipine treatment; and 5) an informed 
consent from the patient to participate in the study.
Exclusion criteria
Exclusion criteria were as follows: 1) known sec-
ondary hypertension and/or dyslipidemia; 2) target BP 
and/or lipid levels achieved by the ongoing therapy; 3) 
known adverse eff ects from previous experience or 
present contraindications to any of the atorvastatin/
amlodipine SPC components; 4) patients already on 
maximal daily dose of amlodipine (10 mg) and/or 
atorvastatin (80 mg), not achieving the target BP and/
or lipid levels; 5) patient’s refusal to be treated with the 
atorvastatin/amlodipine SPC; and 6) impossibility of 
patient follow-up in the course of 3 months for what-
ever reason.
Among all patients, 231 (95.1%) had antihyperten-
sive treatment, but had not achieved the target BP val-
ues despite combination therapy with 2 to 3 drugs in 
most of them (218 of 231, 94.4%). An angiotensin-
converting enzyme inhibitor had been included in 
therapy of 118 (48.6%) patients, a calcium channel 
blocker was taken by 81 (33.3%), an angiotensin II-
receptor blocker by 88 (36.2%), a beta-blocker by 152 
(62.6%), a thiazide diuretic by 19 (7.8%), and other 
BP-lowering drugs by 28 (11.5%) patients. Th e mean 
number of antihypertensive tablets received by the hy-
pertensive patients was 3.0±1.5 (0-8): 2 tablets by 48 
(22.0%), 3 tablets by 77 (35.3%), 4 tablets by 39 
(17.9%) and 5 tablets by 25 (10.3%) patients.
Sixty-seven (27.6%) patients had been on statin 
treatment before inclusion in the study, and 31 (46.3%) 
of them had received atorvastatin.
All patients were evaluated for CV risk. Th e Sys-
tematic COronary Risk Evaluation (SCORE) mod-
el5,8 was used to assess the absolute 10-year risk of fatal 
cardiac event in asymptomatic patients with cardio-
vascular RF. Th e added CV risk was assessed in hyper-
tensives with RF and/or subclinical target organ dam-
age or overt CV or non-cardiac complications. Th e risk 
was found to be moderate in 70 (39.3%) and high in 
173 (59.7%) patients.
All patients enrolled in our study started treatment 
with one of the following doses of the SPC atorvas-
tatin/amlodipine (Gedeon Richter Plc., Hungary): 
10/5, 10/10, 20/5 or 20/10 mg daily with up-titration 
at visit 1 when necessary. Th e dosage was determined 
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by the treating physician based on the BP and LDL-C 
values and the level of individual CV risk as well.
Th e concomitant medication was continued unless 
it was a calcium channel blocker or statin. Th e period 
of patient follow-up was 3 months with clinical visits 
at the end of months 1 and 3 after initiation of SPC 
atorvastatin/amlodipine treatment. At baseline and at 
each follow-up visit, offi  ce BP measurement was per-
formed after 10-min rest in sitting position, twice at 
the non-dominant arm with 1-min interval between 
the measurements. During follow-up visits, detailed 
medical history was taken about treatment regimen, 
home BP control and presence of adverse eff ects (AE). 
In patients not achieving the target BP and/or LDL-
C levels recommended by the current Guidelines of 
the European Society of Cardiology, an increase in the 
dose of the researched combination was considered.
At baseline and at month 3, the following lipid pa-
rameters were examined: TC, LDL-C, high-density li-
poprotein cholesterol (HDL-C) and triglycerides (TG).
Statistics
Statistical analysis was carried out with SPSS sta-
tistical package, version 16.0 (SPSS Inc, Chicago, IL, 
USA). Data were expressed by frequencies and per-
centages for categorical variables, and by minimal, 
maximal, mean values and standard deviation for con-
tinuous variables. Comparisons were made by using 
the independent χ2-test, t-test, and ANOVA. Th e level 
of statistical signifi cance was set at p<0.05.
Results
Figure 1 shows the prescription rate of the ana-
lyzed 4 dose combinations of atorvastatin/amlodipine 
at baseline, month 1 and month 3.
Th e mean systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) values of the analyzed 
group of patients at baseline and at the end of month 
1 and 3 are shown in Table 1, whereas Figure 2 illus-
trates the dynamics of BP during the follow-up period.
Th e normalization rate of BP, defi ned for our study 
as SBP <140 and DBP <90 mm Hg (<85 mm Hg for 
diabetic patients) in accordance with the current 2013 
ESC Guidelines for treatment of arterial hyperten-
sion5 was as follows:
• at month 1: SPB <140 mm Hg was achieved by 
147 (60.5%) and DBP <90 mm Hg by 183 
(75.3%) patients; p<0.0001 vs. baseline;
• at month 3: SPB <140 mm Hg was achieved by 
175 (72.1%) and DBP <90 mm Hg by 221 
(91.0%) patients; p<0.0001 vs. baseline and 
month 1.
Fig. 1. Prescription of diff erent atorvastatin/amlodipine combinations to study 
population at baseline, month 1 and month 3.
10/5 mg: p=0.03 for baseline vs. month 1 and month 3; p=NS for month 1 vs. month 3;
10/10 mg: p=0.01 for baseline vs. month 1 and p=0.04 vs. month 3, p=0.03 for month 1 
vs. month 3;
20/5 mg: p<0.0001 for baseline vs. month 1 and month 3; p=NS for month 1 vs. month 3;
20/10 mg: p=0.02 for baseline vs. month 1 and month 3; p=NS for month 1 vs. month 3.
NS = nonsignifi cant; p = level of statistical signifi cance
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Table 1. Systolic and diastolic blood pressure values 
in study population at baseline and at follow-up visits 















SBP 146 200 155.67 16.21
Baseline 
DBP 90 118 92.03 9.23
SBP 
– month 1 107 183 140.69 13.59
DBP 
– month 1 70 105 83.41 6.32
SBP 
– month 3 112 148 136.88 26.97
DBP 
– month 3 65 90 80.64 5.07
DBP = diastolic blood pressure; SBP = systolic blood pressure
Table 2. Systolic and diastolic blood pressure values 
in study patients treated with the lowest dose 















SBP 146 197 153.17 15.03
Baseline 
DBP 90 110 90.81 9.02
SBP 
– month 1 108 182 138.55 12.80
DBP 
– month 1 70 95 82.71 5.59
SBP 
– month 3
116 167 130.36 12.99
DBP 
– month 3 65 90 80.59 5.47
DBP = diastolic blood pressure; SBP = systolic blood pressure
Th e mean SBP and DBP values of patients treated 
with the most frequently prescribed dosage of 10/5 mg 
of the SPC of atorvastatin/amlodipine are shown in 
Table 2, whereas Figure 3 illustrates the dynamics of 
their BP during the follow-up period.
Th e normalization rate of BP of the patients treated 
with atorvastatin/amlodipine 10/5 mg was as follows:
• at month 1: SPB <140 mm Hg was achieved by 
64 (45.7%) and DBP <90 mm Hg by 116 
(82.6%) patients; p<0.0001 vs. baseline;
• at month 3: SPB <140 mm Hg was achieved 
by 108 (76.9%) and DBP <90 mm Hg by 127 
(90.6%) patients, p<0.0001 vs. baseline and 
month 1.
Th e mean values of the lipid parameters at base-
line and at month 3 are shown in Table 3, whereas the 
dynamics of TC and LDL-C are illustrated in Figu-
re 4.
Target values of the analyzed lipid parameters 
 (according to the recommendations of the current 
Fig. 2. Dynamics of systolic and diastolic blood pressure 
in study population after initiation of treatment 
with atorvastatin/amlodipine.
DBP = diastolic blood pressure; SBP = systolic blood pressure; NS 
= nonsignifi cant; p = level of statistical signifi cance
Fig. 3. Dynamics of systolic and diastolic 
blood pressure in patients treated with 10/5 mg 
atorvastatin/amlodipine.
DBP = diastolic blood pressure; SBP = systolic blood pressure; 
p = level of statistical signifi cance
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HDL-C 0.5 2.2 1.3 0.5
Baseline TG 0.6 6.0 2.1 0.8
TC – month 3 2.9 6.4 5.1 0.9
LDL-C 
– month 3 0.8 4.6 2.9 1.0
HDL-C 
– month 3 0.8 2.5 1.4 0.5
TG – month 3 0.6 4.6 1.6 0.7
HDL-C = high-density lipoprotein cholesterol; LDL-C = low-
density lipoprotein cholesterol; TC = total cholesterol; TG = tri-
glycerides
Table 4. Values of lipid parameters in patients 













Baseline TC 5.4 9.7 6.3 1.2
Baseline 
LDL-C 3.5 7.9 4.3 1.2
Baseline 
HDL-C 0.5 1.9 1.3 0.4
Baseline TG 0.6 3.5 1.9 0.7
TC – month 3 3.3 6.4 5.2 1.0
LDL-C 
– month 3 1.0 5.7 3.1 1.0
HDL-C 
– month 3 0.8 2.1 1.3 0.4
TG – month 3 0.6 4.4 1.7 0.7
HDL-C = high-density lipoprotein cholesterol; LDL-C = low-
density lipoprotein cholesterol; TC = total cholesterol; TG = tri-
glycerides
ESC Guidelines for cardiovascular prevention)8 were 
achieved at month 3 as follows:
• patients at moderate CV risk: LDL-C <3.0 
mmol/L in 52 (74.3%) and TC <5.0 mmol/L in 
55 (78.6%) patients; p<0.0001 vs. baseline;
• patients at high CV risk: LDL-C <2.5 mmol/L 
in 108 (62.4%) and TC values <4.5 mmol/L in 
114 (65.9%) patients; p<0.000 1 vs. baseline.
Th e values of lipid parameters in patients treated 
with the most frequently prescribed dosage of 10/5 mg 
of the SPC of atorvastatin/amlodipine are shown in 
Table 4, whereas Figure 5 shows the dynamics of TC 
and LDL-C.
Treatment with the lowest dose of 10/5 mg of 
the SPC of atorvastatin/amlodipine achieved target 
values of the analyzed lipid parameters at month 3 as 
follows:
Fig. 4. Dynamics of total cholesterol and low-density 
lipoprotein cholesterol in study population.
TC = total cholesterol; LDL-C = low-density lipoprotein choles-
terol; p = level of statistical signifi cance
Fig. 5. Dynamics of total cholesterol and low-density 
lipoprotein cholesterol in patients treated with 10/5 mg 
atorvastatin/amlodipine.
TC = total cholesterol; LDL-C = low-density lipoprotein choles-
terol; p = level of statistical signifi cance
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• patients at moderate CV risk: LDL-C values 
<3.0 mmol/L in 37 (63.8%) and TC values <5.0 
mmol/L in 39 (67.2%) patients; p<0.0001 vs. 
baseline;
• patients at high CV risk: LDL-C <2.5 mmol/L 
in 24 (38.7%) and TC values <4.5 mmol/L in 28 
(45.2%) patients; p<0.0001 vs. baseline.
On clinical visits at months 1 and 3, we recorded 
the following adverse events (AE) that could be at-
tributed to the treatment with the SPC of atorvas-
tatin/amlodipine:
• mild to moderate facial fl ush: 2 (1.1%) patients 
at month 1 and 1 (0.6%) patient at month 3;
• mild to moderate swelling edema of lower ex-
tremities: 6 (3.4%) patients at month 1 and 
month 3 each;
• mild to moderate headache: 3 (1.7%) patients at 
month 1, whereas none of the patients com-
plained of headache at month 3;
• mild to moderate myalgia: 2 (1.1%) patients at 
month 1 and month 3 each.
Treatment with the investigated SPC of atorvas-
tatin/amlodipine was discontinued in nine (3.7%) pa-
tients because of AE (swelling edema and/or head-
ache); three of them stopped treatment at week 2, four 
patients at month 1 and two patients at month 2.
Discussion
In our study, treatment of patients with the SPC of 
atorvastatin and amlodipine led to signifi cant reduc-
tion of both blood pressure and LDL-C as important 
indicators of CV risk. Th e mean reduction of BP across 
all dose regimens used (from 10/5 mg to 20/10 mg) 
was ~12% for SBP and DBP each. Th e percentage of 
patients achieving the target BP values at the end of 
the study was high (72.1% and 91.0% for SBP and 
DBP, respectively).
Our results were comparable to those published by 
Kékes17. In their study, 2606 patients with HTN and 
dyslipidemia were treated with an SPC of atorvastatin 
and amlodipine. All dosage regimens from 10/5 to 
20/10 mg were analyzed. Th e mean baseline SBP and 
DBP values were 155.9 and 90.2 mm Hg and they 
were reduced at month 3 to 136.9 and 83.6 mm Hg, 
respectively. At the end of the study, 86.5% of the pa-
tients reached the target BP levels (<140/90 mm Hg)17.
In our study, the analyzed SPCs also demonstrated 
a statistically signifi cant lipid-lowering eff ect; the val-
ues of TC and LDL-C were reduced by ~23% and 
34%, respectively, compared to baseline values. In the 
study performed by Kékes et al., LDL-cholesterol was 
reduced from the mean value of 3.45 mmol/L to 2.49 
mmol/L after 3 months of treatment and 76.4% of the 
patients reached the target LDL-C levels at the end of 
the study17.
In more than half of our patients, the lowest dosage 
of the SPC of atorvastatin/amlodipine was prescribed 
at inclusion in the study (individual decision of the 
treating physician) and this regimen was maintained 
until the end of the study in 49% of patients. Th is dos-
age achieved 15% additional SBP and 11% DBP re-
duction when added to the ongoing antihypertensive 
therapy. Th e mean reduction of the analyzed lipid pa-
rameters by this dosage of atorvastatin/amlodipine 
was by ~18% for TC and by ~28% for LDL-C. Reduc-
tion of LDL-C <3.0 mmol/L was achieved by 46.5% 
of the patients treated with the 10/5 mg SPC of ator-
vastatin/amlodipine. It means that the low-dose com-
bination of atorvastatin/amlodipine could be a reason-
able choice for a large number of patients with moder-
ate to high CV risk and mild to moderate elevation of 
BP and LDL-C.
Our results could also be compared with the results 
from several other studies. In the Gemini Study (1220 
patients with uncontrolled HTN and dyslipidemia in-
cluded), eight dosage regimens of an SPC of amlodip-
ine/atorvastatin (from 5/10 to 10/80 mg) were elec-
tively titrated to improve blood pressure and lipid con-
trol18. At baseline, the mean BP was 146.6/87.9 mm 
Hg and mean LDL-C was 152.9 mg/dL. At the end 
of the study, 57.7% of patients achieved both their BP 
and LDL-C goals. Th e mean dose of the study medi-
cation at the end point was amlodipine component 7.1 
mg and atorvastatin component 26.2 mg18.
In the CAPABLE clinical trial (499 patients with 
HTN and dyslipidemia included), the SPC of amlo-
dipine/atorvastatin was also administered in one of the 
8 dosage regimens available (from 5/10 to 10/80 mg), 
with the dose being titrated according to the interme-
diate results19. At the end point, 48.3% of patients 
reached both their BP and LDL-C goals; 56.8% 
reached BP goals and 73.7% reached LDL-C goals19.
Two other open-label studies conducted in 122 
study centers across the United Kingdom and Canada 
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( JEWEL 1) and 113 centers across 11 European 
countries ( JEWEL 2) evaluated the clinical utility of 
the SPC of amlodipine plus atorvastatin to help pa-
tients across Europe and Canada achieve country-spe-
cifi c targets for BP and LDL-C20. Th e treatment peri-
od was 16 weeks. Among 2245 patients enrolled in 
these studies, 62.9% in JEWEL 1 and 50.6% in JEW-
EL 2 reached both country-specifi c BP and LDL-C 
goals. BP was reduced by 20.4/10.7 and 21.8/12.6 mm 
Hg in JEWEL 1 and JEWEL 2, respectively, and re-
ductions in LDL-C were 0.90 mmol/L and 1.09 
mmol/L, respectively20.
Our results and the reports of other clinical studies 
presented above are quite important. Epidemiologic 
data have suggested that, on average, less than 10% of 
patients with concomitant hypertension and dyslipid-
emia are at target levels for both conditions7,21. Th e 
large benefi ts that can result from simultaneous treat-
ment of hypertension and dyslipidemia and the cur-
rent suboptimal management of these conditions 
worldwide demonstrate that novel solutions are need-
ed to treat the growing number of patients who have 
both of these important CV risk factors. Th e SPC of 
amlodipine/atorvastatin therapy represents such a so-
lution. Usage of single-pill combinations is associated 
with 24% lower risk of the lack of compliance to treat-
ment22. A retrospective cohort study in a large man-
aged-care population (n=8406) showed that patients 
who initiated therapy with both antihypertensive and 
lipid-lowering drugs within 30 days apart were more 
likely to be adherent to both drug regimens over 
time23,24. It has been proven that the high level of pa-
tient compliance to treatment is related to 50% reduc-
tion of CV events24,25.
Treatment with the SPC of atorvastatin/amlodip-
ine was generally well tolerated by our patients. Only 
nine of 243 (3.7%) patients discontinued treatment, 
mostly for AE which were relatively rare, mildly to 
moderately manifested, and often transient. Swelling 
of lower extremities was the most common one, but 
compared to other studies with amlodipine its fre-
quency was lower18-20,26-28. In the Gemini study, 4.8% 
of patients discontinued therapy due to AE18,26. In 
JEWEL 1 and 2 studies, the most common ones were 
peripheral edema (11.0%), joint swelling (2.9%) and 
headache (2.9%), but only edema was linked to study 
treatment20. Similarly, in the CAPABLE clinical trial 
including 499 patients receiving drug therapy, com-
mon treatment-related AE were peripheral edema 
(3.4%) and headache (2.2%), rarely myalgia and con-
stipation (2.0%)19.
It could be suggested that the lower rate of AE in 
our study was because of the use of amlodipine 5 mg in 
the vast majority of patients (78.6%), as well as the 
concomitant treatment with angiotensin-converting 
enzyme inhibitor or angiotensin II-receptor blocker 
(up to 84.8%).
Th e main limitations of our study were as follows: 
1) our research was designed as a prospective but not 
randomized and blinded study; 2) control group was 
not included – the eff ectiveness of the study medica-
tion was not compared to a placebo and/or other drug 
combination (free or SPC); and 3) the follow-up pe-
riod was 3 months and conclusions on long-term effi  -
cacy and safety of the investigated SPC of atorvas-
tatin/amlodipine could not be drawn.
In conclusion, treatment with the SPC of atorvas-
tatin/amlodipine in our study was eff ective in reducing 
both blood pressure and lipid levels and generally well 
tolerated by patients with moderate to high risk.
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Sažetak
UČINKOVITOST I SIGURNOST KOMBINACIJE ATORVASTATINA/AMLODIPINA 
U JEDNOJ TABLETI KOD BOLESNIKA S ARTERIJSKOM HIPERTENZIJOM I DISLIPIDEMIJOM
S. Naydenov Naydenov, N. Margaritov Runev, E. Ivanov Manov i S. Georgieva Torbova-Gigova
Cilj ovoga istraživanja je bio ocijeniti učinkovitost kombinacije atorvastatina/amlodipina u jednoj tableti kod bolesnika s 
arterijskom hipertenzijom, dislipidemijom i umjerenim do visokim kardiovaskularnim rizikom. Ovo prospektivno istraži-
vanje obuhvatilo je 243 bolesnika s arterijskom hipertenzijom, dislipidemijom i umjerenim do visokim kardiovaskularnim 
rizikom, srednje dobi od 63,3±9,8 godina. Bolesnicima je propisana terapija jednim od sljedećih režima doziranja kombina-
cije atorvastatina/amlodipina u jednoj tableti: 10/5, 10/10, 20/5 ili 20/10 mg na dan. Razdoblje praćenja bilo je 3 mjeseca. 
Srednje početne vrijednosti sistoličkog i dijastoličkog tlaka bile su 155,7±16,2 i 92,0±92,0 mm Hg. Krajem 3. mjeseca vrijed-
nosti sistoličkog i dijastoličkog tlaka bile su 136,9±26,9 i 80,6±5,0 mg Hg. Srednje početne vrijednosti ukupnog kolesterola 
i kolesterola niske gustoće bile su 6,6±1,2 i 4,4±1,1 mmol/L. Krajem 3. mjeseca vrijednosti ukupnog kolesterola i kolesterola 
niske gustoće bile su 5,1±0,9 i 2,9±1,0 mmol/L. Terapija analiziranom kombinacijom lijekova prekinuta je kod 9 (3,7%) 
bolesnika zbog neželjenih nuspojava. U zaključku, terapija kombinacijom atorvastatina/amlodipina u jednoj tableti visoko je 
učinkovita i dobro ju podnose bolesnici s arterijskom hipertenzijom, dislipidemijom i umjerenim do visokim kardiovaskular-
nim rizikom.
Ključne riječi: Hipertenzija; Dislipidemije; Kardiovaskularne bolesti; Antihipertonici
